Ascentage Pharma Group International closed an offshore placement, selling 22 million ordinary shares at HKD68.60 per share. The net proceeds of approximately HKD1,492 million will be used for commercialization efforts and global clinical development. The Company’s lead asset, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for CML treatment. The second lead asset, lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies. Ascentage Pharma aims to address unmet medical needs in cancers through innovative drug candidates. The transactions were conducted in accordance with Placing and Subscription Agreement by the Company, the Vendor, J.P. Morgan (Asia Pacific) Limited, and Citigroup Global Markets Limited.

Read more at GlobeNewswire: Ascentage Pharma Announces Closing of Placement Shares in